SRR1314163
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.431
- TNFA_SIGNALING_VIA_NFKB+0.415
- HYPOXIA+0.391
- UV_RESPONSE_UP+0.360
- MYOGENESIS+0.349
- INFLAMMATORY_RESPONSE+0.299
- ESTROGEN_RESPONSE_EARLY+0.288
- MTORC1_SIGNALING+0.287
- APICAL_SURFACE+0.283
- PANCREAS_BETA_CELLS+0.272
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.487
- E2F_TARGETS-0.403
- INTERFERON_GAMMA_RESPONSE-0.321
- G2M_CHECKPOINT-0.314
- BILE_ACID_METABOLISM-0.304
- DNA_REPAIR-0.289
- MITOTIC_SPINDLE-0.244
- WNT_BETA_CATENIN_SIGNALING-0.203
- NOTCH_SIGNALING-0.184
- MYC_TARGETS_V1-0.149
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1465917 | GTEX | — | 0.803 |
| 2 | SRR1489137 | GTEX | — | 0.801 |
| 3 | SRR598332 | GTEX | — | 0.789 |
| 4 | 8F5717EC-3344-48CA-9B0C-FCDED8C0F955 | — | — | 0.782 |
| 5 | SRR816770 | GTEX | — | 0.771 |
| 6 | SRR817715 | GTEX | — | 0.769 |
| 7 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.764 |
| 8 | SRR810319 | GTEX | — | 0.763 |
| 9 | 618FAB92-C578-4144-9BD0-AEE1AFBFA08E | — | — | 0.760 |
| 10 | SRR2932821 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.431 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.415 | Inavolisib | — uncovered |
| HYPOXIA | 0.391 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.360 | Idelalisib | — uncovered |
| MYOGENESIS | 0.349 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.299 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.288 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.287 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.283 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.272 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.266 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.261 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.243 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.241 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.238 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.237 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.234 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.232 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.201 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |